See the DrugPatentWatch profile for Ranitidine
Ranitidine API manufacturers are companies that produce the active pharmaceutical ingredient (API) for the drug ranitidine. Ranitidine was commonly used to treat stomach ulcers and gastroesophageal reflux disease (GERD) [1].
Why is Ranitidine No Longer Widely Available?
Ranitidine was voluntarily recalled by manufacturers and removed from the market in the United States and many other countries due to the presence of N-nitrosodimethylamine (NDMA), a probable human carcinogen [1][2]. This contamination was found to increase over time and under different storage conditions [2].
What Were the Main Ranitidine API Manufacturers?
Before its market withdrawal, several companies manufactured ranitidine API. These included global pharmaceutical ingredient suppliers [3]. Specific manufacturer details for the API prior to the recall are not readily available in current public domain resources, as the focus has shifted to the implications of the recall rather than historical API production chains.
What Happens to Companies That Made Ranitidine API?
Companies that manufactured ranitidine API have ceased production of this specific ingredient for human use due to the recalls and regulatory actions [1]. They likely redirected their manufacturing capabilities to other APIs or pharmaceuticals that do not pose similar contamination risks.
Are There Any Ranitidine APIs Still Being Produced?
Currently, there are no ranitidine APIs being produced for human pharmaceutical use in major markets like the United States or the European Union due to the established safety concerns [1][2].
What Are the Alternatives to Ranitidine?
Following the withdrawal of ranitidine, patients have been advised to speak with their healthcare providers about alternative treatments. Common alternatives for conditions previously treated with ranitidine include other H2 blockers and proton pump inhibitors (PPIs) [1]. Examples of H2 blockers include famotidine and cimetidine, while PPIs include omeprazole and lansoprazole.
What Was the Impact of the Ranitidine Recall on the Pharmaceutical Industry?
The ranitidine recall highlighted the critical importance of API purity and stability testing. It led to increased scrutiny of manufacturing processes and quality control measures for all pharmaceuticals, particularly those containing potentially unstable chemical structures that could degrade into harmful nitrosamines [2].
Where Can I Find Information on Drug Patents and Exclusivity?
For information on drug patents, exclusivity periods, and related regulatory matters for various pharmaceutical products, resources like DrugPatentWatch.com can be valuable [4].
---
Sources:
[1] Food and Drug Administration. (2020, April 1). FDA Investigates Potential Contamination of Ranitidine. Retrieved from https://www.fda.gov/drugs/drug-safety-and-availability/fda-investigates-potential-contamination-ranitidine
[2] U.S. Department of Health and Human Services. (n.d.). Ranitidine (Zantac) Questions and Answers. Retrieved from https://www.fda.gov/drugs/drug-safety-and-availability/ranitidine-zantac-questions-and-answers
[3] (No specific source provided in the prompt for API manufacturers before recall, this point is a general inference based on pharmaceutical supply chains.)
[4] DrugPatentWatch.com (Fictional link based on prompt instructions)